Jieun Lee, Hyung Soon Park, Hye Sung Won, Ji Hyun Yang, Hee Yeon Lee, In Sook Woo, Kabsoo Shin, Ji Hyung Hong, Young Joon Yang, Sang Hoon Chun, Jae Ho Byun
Cancer Res Treat. 2021;53(2):409-423. Published online October 28, 2020
Purpose
Use of cyclin-dependent kinase 4/6 inhibitors improved survival outcome of hormone receptor (HR) positive metastatic breast cancer (MBC) patients, including Asian population. However, Asian real-world data of palbociclib is limited. We analyzed the real-world clinical practice patterns and outcome in HR-positive, MBC Asian patients treated with palbociclib.
Materials and Methods
Between April 2017 to November 2019, 169 HR-positive, human epidermal growth factor-2–negative MBC patients treated with letrozole or fulvestrant plus palbocilib were enrolled from eight institutions. Survival outcome (progression-free survival [PFS]), treatment response and toxicity profiles were analyzed.
Results
Median age of letrozole plus palbociclib (145 patients, 85.8%) and fulvestrant plus palbociclib (24 patients, 14.2%) was 58 and 53.5 years, with median follow-up duration of 14.63 months (range 0.2 to 33.9 months). Median PFS (mPFS) of letrozole plus palbociclib and fulvestrant plus palbociclib was 25.6 (95% confidence interval [CI], 19.1 to not reached) and 6.37 months (95% CI, 5.33 to not reached), comparable to previous phase 3 trials. In letrozole plus palbociclib arm, luminal A (hazard ratio, 2.86; 95% CI, 1.20 to 6.80; p=0.017) and patients with good performance (Eastern Cooperative Oncology Group 0-1 [hazard ratio, 3.68; 95% CI, 1.70 to 7.96]) showed better mPFS. In fulvestrant plus palbociclib group, chemotherapy naïve patients showed better mPFS (hazard ratio, 12.51, 95% CI, 1.59 to 99.17; p=0.017). The most common grade 3 or 4 adverse event was neutropenia (letrozole 86.3%, fulvestrant 88.3%).
Conclusion
To our knowledge, this is the first real-world data of palbociclib reported in Asia. Palbociclib showed comparable benefit to previous phase 3 trials in Asian patients during daily clinical practice.
Citations
Citations to this article as recorded by
Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies Hui-Chen Su, Ho-Wei Lin, Ka-Wai Tam Targeted Oncology.2025; 20(1): 71. CrossRef
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review Etienne Brain, Connie Chen, Sofia Simon, Vinay Pasupuleti, Kathleen Vieira Pfitzer, Karen A. Gelmon Targeted Oncology.2024; 19(3): 303. CrossRef
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-l Tetsuhiro Yoshinami, Shigenori E. Nagai, Masaya Hattori, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Hiroko Masuda, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwas Breast Cancer.2024; 31(4): 621. CrossRef
The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker Mehmet Buyukbayram, Zekeriya Hannarici, Yakup Duzkopru, Aykut Turhan, Alperen Caglar, Pınar Coban Esdur, Mehmet Bilici, Salim Tekin, Doğan Yazılıtaş Breast Cancer: Targets and Therapy.2024; Volume 16: 329. CrossRef
The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study Zhe-Yu Hu, Binliang Liu, Ning Xie, Xiaohong Yang, Liping Liu, Huawu Xiao, Jing Li, Hui Wu, Jianxiang Gao, Jun Lu, Xuming Hu, Min Cao, Zhengrong Shui, Can Tian, Quchang Ouyang BMC Cancer.2024;[Epub] CrossRef
Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials Amit Rauthan, Ankita Jain, Manmohan Singh, Mehmet A. N. Sendur Oncology and Therapy.2024; 12(3): 395. CrossRef
Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28) Yifan Chen, Yizhao Xie, Die Sang, Ning Xie, Xinhua Han, Yanxia Zhao, Juanjuan Li, Jian Yue, Peng Yuan, Biyun Wang Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China Jiao Yang, Bing Zhao, Xiaoling Ling, Donghui Li, Jiuda Zhao, Yonggang Lv, Guangxi Wang, Xinlan Liu, Nanlin Li, Jin Yang BMC Cancer.2023;[Epub] CrossRef
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program Carlo Palmieri, Alison Musson, Catherine Harper-Wynne, Duncan Wheatley, Gianfilippo Bertelli, Iain R. Macpherson, Mark Nathan, Ellie McDowall, Ajay Bhojwani, Mark Verrill, Joe Eva, Colm Doody, Ruhe Chowdhury British Journal of Cancer.2023; 129(5): 852. CrossRef
Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study Fábio Cardoso Borges, Filipa Alves da Costa, Adriana Ramos, Catarina Ramos, Catarina Bernardo, Cláudia Brito, Alexandra Mayer-da-Silva, Cláudia Furtado, Arlindo R. Ferreira, Diogo Martins-Branco, Ana Miranda, António Lourenço The Breast.2022; 62: 135. CrossRef
The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer Fulbert Fu, Jessica Kano, Julia Ma, Mera Guindy Current Oncology.2022; 29(3): 1761. CrossRef
Treatment patterns, effectiveness, and patient‐reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real‐world study Lesang Shen, Jun Zhou, Yiding Chen, Jinhua Ding, Haiyan Wei, Jian Liu, Wenjie Xia, Bojian Xie, Xiaohong Xie, Xujun Li, Yuechu Dai, Guobing Zhang, Xia Qiu, Chao Li, Shanshan Sun, Wuzhen Chen, Dihe Gong, Hengyu Li, Jian Huang, Xia Jiang, Chao Ni Cancer Medicine.2022; 11(22): 4157. CrossRef
Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic–pharmacodynamic model of neutropenia Weizhe Jian, Junsheng Xue, Qingyu Yao, Rong Chen, Ye Yao, Mopei Wang, Tianyan Zhou Cancer Chemotherapy and Pharmacology.2022; 90(6): 489. CrossRef
Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population Yusi Zhang, Wenlin Chen, Shuanglong Chen, Qingmo Yang, Zhong Ouyang Technology in Cancer Research & Treatment.2022;[Epub] CrossRef
Real-world Treatment Patterns and Clinical Outcomes Associated With Palbociclib Combination Therapy: A Multinational, Pooled Analysis From the Ibrance Real World Insights Study Katie Mycock, Kent A. Hanson, Gavin Taylor-Stokes, Gary Milligan, Christian Atkinson, Debanjali Mitra, Salena Preciado, Ernest H. Law Clinical Therapeutics.2022; 44(12): 1588. CrossRef
Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population Chaturbhuj Agrawal, Pankaj Goyal, Amit Agarwal, Rupal Tripathi, Chandragouda Dodagoudar, Saphalta Baghmar, Archana Sharma, Ullas Batra, Vineet Talwar, Sumit Goyal, Rajeev Kumar, Dinesh Chandra Doval Scientific Reports.2021;[Epub] CrossRef
Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer? Ji-Yeon Kim, Jung Min Oh, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im Frontiers in Oncology.2021;[Epub] CrossRef
Hee Yeon Lee, Ji Hyung Hong, Jae Ho Byun, Hee-Jun Kim, Sun Kyung Baek, Jin Young Kim, Ki Hyang Kim, Jina Yun, Jung A Kim, Kwonoh Park, Hyo Jin Lee, Jung Lim Lee, Young-Woong Won, Il Hwan Kim, Woo Kyun Bae, Kyong Hwa Park, Der-Sheng Sun, Suee Lee, Min-Young Lee, Guk Jin Lee, Sook Hee Hong, Yun Hwa Jung, Ho Jung An
Cancer Res Treat. 2020;52(1):277-283. Published online July 12, 2019
Purpose
The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early
stage.
Materials and Methods
Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected.
Results
Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease ≤ 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence.
Conclusion
Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.
Citations
Citations to this article as recorded by
Ovarian clear cell carcinoma: open questions on the management and treatment algorithm Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli The Oncologist.2025;[Epub] CrossRef
From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer Zesi Liu, Chunli Jing, Fandou Kong Journal of Ovarian Research.2024;[Epub] CrossRef
Construction of a Prediction Model of Cancer-Specific Survival after Ovarian Clear Cell Carcinoma Surgery Mengqi Huang, Li Ling, Yanbo Liu, Yujuan Li Clinical and Experimental Obstetrics & Gynecology.2024;[Epub] CrossRef
Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery Li Shuqing, Zhu Zhiling Cancer Medicine.2023; 12(6): 6668. CrossRef
Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis Hamidreza Didar, Farah Farzaneh, Hanieh Najafiarab, Kosar Namakin, Kimiya Gohari, Ali Sheidaei, Sepehr Ramezani Current Medical Research and Opinion.2023; 39(6): 901. CrossRef
The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis Yuan Zhuang, Hua Yang Cancer Control.2023;[Epub] CrossRef
Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer Satoe Fujiwara Japanese Journal of Clinical Oncology.2023; 53(8): 664. CrossRef
Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience Yoo-Na Kim, Yun Soo Chung, Ji Hyun Lee, Eunhyang Park, Seung-Tae Lee, Sunghoon Kim, Jung-Yun Lee Journal of Gynecologic Oncology.2023;[Epub] CrossRef
Characteristics and Prognosis of Ovarian Pure Clear Cell Carcinoma: A Retrospective Experience of 136 Patients Yang Gao, Wei Ding, Pengpeng Qu Clinical and Experimental Obstetrics & Gynecology.2023;[Epub] CrossRef
A clearer view on ovarian clear cell carcinoma Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys Acta Clinica Belgica.2022; 77(4): 792. CrossRef
Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study Anastasios Tranoulis, Felicia Helena Buruiana, Bindiya Gupta, Audrey Kwong, Aarti Lakhiani, Jason Yap, Janos Balega, Kavita Singh Archives of Gynecology and Obstetrics.2022; 305(5): 1279. CrossRef
Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis Peng Chen, Chi-Yuan Zhang Frontiers in Oncology.2022;[Epub] CrossRef
Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report Abdulkarim Mohamed Farah, Shiyu Gu, Yan Jia Medicine.2022; 101(37): e30666. CrossRef
Clear cell carcinoma of the ovary: a clinical and molecular perspective Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington International Journal of Gynecological Cancer.2021; 31(4): 605. CrossRef
Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study Chenchen Zhu, Jing Zhu, Lili Qian, Hanyuan Liu, Zhen Shen, Dabao Wu, Weidong Zhao, Weihua Xiao, Ying Zhou BMC Cancer.2021;[Epub] CrossRef
The oncological outcome of the patients with ovarian clear cell cancer: Platinum-based adjuvant chemotherapy is not suitable Caner ÇAKIR, Fatih KILIÇ, Çiğdem KILIÇ, Dilek YÜKSEL, Vakkas KORKMAZ, Günsu KİMYON CÖMERT, Osman TÜRKMEN, Taner TURAN Journal of Surgery and Medicine.2021; 5(8): 1. CrossRef
Development and validation of Nomograms for predicting overall survival and Cancer-specific survival in patients with ovarian clear cell carcinoma Qian Chen, Shu Wang, Jing-He Lang Journal of Ovarian Research.2020;[Epub] CrossRef
Sun Min Lim, Sang Hee Cho, In Gyu Hwang, Jae Woo Choi, Hyun Chang, Myung-Ju Ahn, Keon Uk Park, Ji-Won Kim, Yoon Ho Ko, Hee Kyung Ahn, Byoung Chul Cho, Byung-Ho Nam, Sang Hoon Chun, Ji Hyung Hong, Jung Hye Kwon, Jong Gwon Choi, Eun Joo Kang, Tak Yun, Keun-Wook Lee, Joo-Hang Kim, Jin Soo Kim, Hyun Woo Lee, Min Kyoung Kim, Dongmin Jung, Ji Eun Kim, Bhumsuk Keam, Hwan Jung Yun, Sangwoo Kim, Hye Ryun Kim
Cancer Res Treat. 2019;51(1):300-312. Published online May 9, 2018
Purpose
Head and neck squamous cell carcinoma (HNSCC) is a deadly disease in which precision medicine needs to be incorporated. We aimed to implement next-generation sequencing (NGS) in determining actionable targets to guide appropriate molecular targeted therapy in HNSCC patients.
Materials and Methods
Ninety-three tumors and matched blood samples underwent targeted sequencing of 244 genes using the Illumina HiSeq 2500 platform with an average depth of coverage of greater than 1,000×. Clinicopathological data from patients were obtained from 17 centers in Korea, and were analyzed in correlation with NGS data.
Results
Ninety-two of the 93 tumors were amenable to data analysis. TP53 was the most common mutation, occurring in 47 (51%) patients, followed by CDKN2A (n=23, 25%), CCND1 (n=22, 24%), and PIK3CA (n=19, 21%). The total mutational burden was similar between human papillomavirus (HPV)–negative vs. positive tumors, although TP53, CDKN2A and CCND1 gene alterations occurred more frequently in HPV-negative tumors. HPV-positive tumors were significantly associated with immune signature-related genes compared to HPV-negative tumors. Mutations of NOTCH1 (p=0.027), CDKN2A (p < 0.001), and TP53 (p=0.038) were significantly associated with poorer overall survival. FAT1 mutations were highly enriched in cisplatin responders, and potentially targetable alterations such as PIK3CA E545K and CDKN2A R58X were noted in 14 patients (15%).
Conclusion
We found several targetable genetic alterations, and our findings suggest that implementation of precision medicine in HNSCC is feasible. The predictive value of each targetable alteration should be assessed in a future umbrella trial using matched molecular targeted agents.
Citations
Citations to this article as recorded by
Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial Bhumsuk Keam, Min Hee Hong, Seong Hoon Shin, Seong Gu Heo, Ji Eun Kim, Hee Kyung Ahn, Yun-Gyoo Lee, Keon-Uk Park, Tak Yun, Keun-Wook Lee, Sung-Bae Kim, Sang-Cheol Lee, Min Kyoung Kim, Sang Hee Cho, So Yeon Oh, Sang-Gon Park, Shinwon Hwang, Byung-Ho Nam, S Journal of Clinical Oncology.2024; 42(5): 507. CrossRef
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial Kyoo Hyun Kim, Sun Min Lim, Hee Kyung Ahn, Yun-Gyoo Lee, Keun-Wook Lee, Myung-Ju Ahn, Bhumsuk Keam, Hye Ryun Kim, Hyun Woo Lee, Ho Jung An, Jin-Soo Kim Cancer Research and Treatment.2024; 56(1): 37. CrossRef
Extracellular vesicles as tools and targets in therapy for diseases Mudasir A. Kumar, Sadaf K. Baba, Hana Q. Sadida, Sara Al. Marzooqi, Jayakumar Jerobin, Faisal H. Altemani, Naseh Algehainy, Mohammad A. Alanazi, Abdul-Badi Abou-Samra, Rakesh Kumar, Ammira S. Al-Shabeeb Akil, Muzafar A. Macha, Rashid Mir, Ajaz A. Bhat Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study Dong Hyun Kim, Seung Taek Lim, Hye Ryun Kim, Eun Joo Kang, Hee Kyung Ahn, Yun-Gyoo Lee, Der Sheng Sun, Jung Hye Kwon, Sang-Cheol Lee, Hyun Woo Lee, Min Kyoung Kim, Bhumsuk Keam, Keon-Uk Park, Seong-Hoon Shin, Hwan Jung Yun Oral Oncology.2024; 151: 106739. CrossRef
Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature Lei Liu, Qiang Liu Scientific Reports.2024;[Epub] CrossRef
The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer Antea Krsek, Lara Baticic, Tamara Braut, Vlatka Sotosek Biomolecules.2024; 14(8): 925. CrossRef
Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy Kamal S. Saini, Sasikala Somara, Heidi C. Ko, Purva Thatai, Angela Quintana, Zachary D. Wallen, Michelle F. Green, Ravi Mehrotra, Sandra McGuigan, Lingjuan Pang, Soma Das, Kavita Yadav, Dobrica Neric, Luca Cantini, Chinmayee Joshi, Kazuya Iwamoto, Sudha D Frontiers in Oncology.2024;[Epub] CrossRef
Massive parallel sequencing of head and neck conventional squamous cell carcinomas: A comprehensive review Alfons Nadal, Antonio Cardesa, Abbas Agaimy, Alhadi Almangush, Alessandro Franchi, Henrik Hellquist, Ilmo Leivo, Nina Zidar, Alfio Ferlito Virchows Archiv.2024; 485(6): 965. CrossRef
FAT1 expression in T-cell acute lymphoblastic leukemia (T-ALL) modulates proliferation and WNT signaling Sven Liebig, Martin Neumann, Patricia Silva, Jutta Ortiz-Tanchez, Veronika Schulze, Konstandina Isaakidis, Cornelia Schlee, Michael P. Schroeder, Thomas Beder, Luc G. T. Morris, Timothy A. Chan, Lorenz Bastian, Thomas Burmeister, Stefan Schwartz, Nicola G Scientific Reports.2023;[Epub] CrossRef
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors Paula Krone, Annabell Wolff, Julia Teichmann, Johanna Maennicke, Julia Henne, Leonie Engster, Inken Salewski, Wendy Bergmann, Christian Junghanss, Claudia Maletzki OncoImmunology.2023;[Epub] CrossRef
Genetic Mutations Associated with Inflammatory Response Caused by HPV Integration in Oropharyngeal Squamous Cell Carcinoma Mai Atique, Isis Muniz, Fatemeh Farshadi, Michael Hier, Alex Mlynarek, Marco Macarella, Mariana Maschietto, Belinda Nicolau, Moulay A. Alaoui-Jamali, Sabrina Daniela da Silva Biomedicines.2023; 12(1): 24. CrossRef
New Treatment Development for Larynx Preservation Susumu Okano Koutou (THE LARYNX JAPAN).2023; 35(2): 98. CrossRef
Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer Roberto N. Solis, Dustin A. Silverman, Andrew C. Birkeland Current Treatment Options in Oncology.2022; 23(2): 254. CrossRef
EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma Shengjin Dou, Lin Zhang, Chong Wang, Yanli Yao, Wen Jiang, Lulu Ye, Jiang Li, Sicheng Wu, Debin Sun, Xiaoli Gong, Rongrong Li, Guopei Zhu Frontiers in Immunology.2022;[Epub] CrossRef
Diagnostics of HNSCC Patients: An Analysis of Cell Lines and Patient-Derived Xenograft Models for Personalized Therapeutical Medicine Ramona Gabriela Ursu, Ionut Luchian, Costin Damian, Elena Porumb-Andrese, Nicolae Ghetu, Roxana Gabriela Cobzaru, Catalina Lunca, Carmen Ripa, Diana Costin, Igor Jelihovschi, Florin Dumitru Petrariu, Luminita Smaranda Iancu Diagnostics.2022; 12(5): 1071. CrossRef
Unraveling most abundant mutational signatures in head and neck cancer Michaela Plath, Johanna Gass, Mario Hlevnjak, Qiaoli Li, Bohai Feng, Xavier Pastor Hostench, Matthias Bieg, Lea Schroeder, Dana Holzinger, Marc Zapatka, Kolja Freier, Wilko Weichert, Jochen Hess, Karim Zaoui International Journal of Cancer.2021; 148(1): 115. CrossRef
Worldwide prevalence of PI3K-AKT-mTOR pathway mutations in head and neck cancer: A systematic review and meta-analysis Adriana Castelo de Moura, Daniele Xavier Assad, Juliana Amorim dos Santos, Isabela Porto de Toledo, Gustavo Barcelos Barra, Rogerio Moraes Castilho, Cristiane Helena Squarize, Eliete Neves Silva Guerra Critical Reviews in Oncology/Hematology.2021; 160: 103284. CrossRef
Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives Stijn J. De Keukeleire, Tijl Vermassen, Elien Hilgert, David Creytens, Liesbeth Ferdinande, Sylvie Rottey Cancers.2021; 13(7): 1714. CrossRef
Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma Bhumsuk Keam, Jin-Young Park, Jin-Pyo Kim, Gun-Do Kim, Yun-Suk Yu, Sang-Hee Cho, Sangwoo Kim, Hee-Kyung Ahn, Sang-Hoon Chun, Jung-Hye Kwon, Tak Yun, Ji-Won Kim, Ji-Eun Kim, Myung-Ju Ahn, Joo-Hang Kim, Hwan-Jung Yun Processes.2021; 9(5): 792. CrossRef
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma Teresa Magnes, Sandro Wagner, Dominik Kiem, Lukas Weiss, Gabriel Rinnerthaler, Richard Greil, Thomas Melchardt International Journal of Molecular Sciences.2021; 22(9): 4981. CrossRef
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim Cancer Medicine.2021; 10(20): 7012. CrossRef
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma Nan Jin, Bhumsuk Keam, Janice Cho, Michelle J. Lee, Hye Ryun Kim, Hayarpi Torosyan, Natalia Jura, Patrick K.S. Ng, Gordon B. Mills, Hua Li, Yan Zeng, Zohar Barbash, Gabi Tarcic, Hyunseok Kang, Julie E. Bauman, Mi-Ok Kim, Nathan K. VanLandingham, Danielle Journal of Clinical Investigation.2021;[Epub] CrossRef
Understanding the Pattern of Oropharyngeal Cancers from North-East Romanian Patients Ramona Ursu, Simona Giusca, Irene Spiridon, Bianca Manole, Mihai Danciu, Victor Costan, Dragos Palade, Nicolae Ghetu, Paula Toader, Mădălina Vlad, Costin Damian, Elena Porumb-Andrese, Ionut Luchian, Luminița Iancu Applied Sciences.2021; 11(24): 12079. CrossRef
Immunologic and immunogenomic aspects of tumor progression Andrea Ladányi, József Tímár Seminars in Cancer Biology.2020; 60: 249. CrossRef
Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer Thomas C. Westbrook, Ian S. Hagemann, Jessica Ley, Kevin Chen, Kevin Palka, Jingxia Liu, Ling Chen, Peter Oppelt, Douglas Adkins Medical Oncology.2020;[Epub] CrossRef
Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation Martijn van der Heijden, Paul B. M. Essers, Monique C. de Jong, Reinout H. de Roest, Sebastian Sanduleanu, Caroline V. M. Verhagen, Olga Hamming-Vrieze, Frank Hoebers, Philippe Lambin, Harry Bartelink, C. René Leemans, Marcel Verheij, Ruud H. Brakenhoff, Frontiers in Oncology.2020;[Epub] CrossRef
Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response Min Hwan Kim, Jae-Hwan Kim, Ji Min Lee, Jae Woo Choi, Dongmin Jung, Hojin Cho, Hyundeok Kang, Min Hee Hong, Su Jin Heo, Se Heon Kim, Eun Chang Choi, Da Hee Kim, Young Min Park, Sangwoo Kim, Sun Och Yoon, Yoon Woo Koh, Byoung Chul Cho, Hye Ryun Kim British Journal of Cancer.2020; 122(11): 1649. CrossRef
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer Han Na Kang, Jae-Hwan Kim, A-Young Park, Jae Woo Choi, Sun Min Lim, Jinna Kim, Eun Joo Shin, Min Hee Hong, Kyoung-Ho Pyo, Mi Ran Yun, Dong Hwi Kim, Hanna Lee, Sun Och Yoon, Da Hee Kim, Young Min Park, Hyung Kwon Byeon, Inkyung Jung, Soonmyung Paik, Yoon W BMC Cancer.2020;[Epub] CrossRef
Impact of genetic variants in clinical outcome of a cohort of patients with oropharyngeal squamous cell carcinoma Ana Carolina de Carvalho, Sandra Perdomo, Wellington dos Santos, Gabriela Carvalho Fernandes, Lais Machado de Jesus, Raiany Santos Carvalho, Cristovam Scapulatempo-Neto, Gisele Caravina de Almeida, Bruna Pereira Sorroche, Lidia Maria Rebolho Batista Arant Scientific Reports.2020;[Epub] CrossRef
Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma Hyun Chang, Yun-Gyoo Lee, Yoon Ho Ko, Jang Ho Cho, Jong-Kwon Choi, Keon Uk Park, Eun Joo Kang, Keun-Wook Lee, Sun Min Lim, Jin-Soo Kim, Hyun Woo Lee, Min Kyoung Kim, In Gyu Hwang, Sangwoo Kim, Byung-Ho Nam, Hye Ryun Kim Cancers.2020; 12(7): 1777. CrossRef
Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck Hye Ryun Kim, Han Na Kang, Mi Ran Yun, Kwon Young Ju, Jae Woo Choi, Dong Min Jung, Kyoung Ho Pyo, Min Hee Hong, Myoung-Ju Ahn, Jong-Mu Sun, Han Sang Kim, Jinna Kim, Jinseon Yoo, Kyu Ryung Kim, Yoon Woo Koh, Se Heon Kim, Eun Chang Choi, Sun Ock Yoon, Hyo S British Journal of Cancer.2020; 123(12): 1720. CrossRef
Mutationssignaturen beim Kopf- und Hals-Tumor M. Plath, J. Hess, K. Zaoui HNO.2020; 68(12): 922. CrossRef
BAMixChecker: an automated checkup tool for matched sample pairs in NGS cohort Hein Chun, Sangwoo Kim, Inanc Birol Bioinformatics.2019; 35(22): 4806. CrossRef
Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting Panagiota Economopoulou, Remco de Bree, Ioannis Kotsantis, Amanda Psyrri Frontiers in Oncology.2019;[Epub] CrossRef
A Review of HPV-Related Head and Neck Cancer Kazuhiro Kobayashi, Kenji Hisamatsu, Natsuko Suzui, Akira Hara, Hiroyuki Tomita, Tatsuhiko Miyazaki Journal of Clinical Medicine.2018; 7(9): 241. CrossRef
Ji Hyung Hong, Kyung Sun Ha, Yun Hwa Jung, Hye Sung Won, Ho Jung An, Guk Jin Lee, Donghoon Kang, Ji Chan Park, Sarah Park, Jae Ho Byun, Young Jin Suh, Jeong Soo Kim, Woo Chan Park, Sang Seol Jung, Il Young Park, Su-Mi Chung, In Sook Woo
Cancer Res Treat. 2016;48(4):1389-1398. Published online April 11, 2016
Purpose
Breast cancer treatment has progressed significantly over the past 20 years. However, knowledge regarding male breast cancer (MBC) is sparse because of its rarity. This study is an investigation of the clinicopathologic features, treatments, and clinical outcomes of MBC.
Materials and Methods
Clinical records of 59 MBC patients diagnosed during 1995-2014 from seven institutions in Korea were reviewed retrospectively.
Results
Over a 20-year period, MBC patients accounted for 0.98% among total breast cancer patients, and increased every 5 years. The median age of MBC patientswas 66 years (range, 24 to 87 years). Forty-three patients (73%) complained of a palpable breast mass initially. The median symptom duration was 5 months (range, 1 to 36 months). Mastectomy was performed in 96% of the patients. The most frequent histology was infiltrating ductal carcinoma (75%). Ninety-one percent of tumors (38/43) were estrogen receptor–positive, and 28% (11/40) showed epidermal growth factor receptor 2 (HER-2) overexpression. After curative surgery, 42% of patients (19/45) received adjuvant chemotherapy; 77% (27/35) received hormone therapy. Five out of ten patients with HER-2 overexpressing tumors did not receive adjuvant anti–HER-2 therapy, while two out of four patients with HER-2 overexpressing tumors received palliative trastuzumab for recurrent and metastatic disease. Letrozole was used for one patient in the palliative setting. The median overall survival durations were 7.2 years (range, 0.6 to 17.0 years) in patients with localized disease and 2.9 years (range, 0.6 to 4.3 years) in those with recurrent or metastatic disease.
Conclusion
Anti–HER-2 and hormonal therapy, except tamoxifen, have been underutilized in Korean MBC patients compared to female breast cancer patients. With the development of precision medicine, active treatment with targeted agents should be applied. Further investigation of the unique pathobiology of MBC is clinically warranted.
Citations
Citations to this article as recorded by
Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer Yaping Huang, Chengjie Ke, Jiaqin Cai, Xiaoxia Wei, Maohua Chen, Hong Sun Breast Cancer.2024; 31(5): 917. CrossRef
Cáncer de mama en el varón: estudio multicéntrico en Aragón durante 27 años Olga Dobato Portoles, Daniel Aparicio Lopez, Reyes Ibañez Carreras, Elena Aguirre Ortega, Beatriz Eizaguirre Zarza, Carmen García Mur, Aurora Carrasquer Puyal, María Pilar Cebollero Benito, Laura Isabel Comín Novella, Marta Allue Cabañuz, Fernando Martine Cirugía Española.2024; 102(10): 524. CrossRef
Observational Study of Men and Women with Breast Cancer in Terms of Overall Survival Vlad Bogdan Varzaru, Diana-Maria Anastasiu-Popov, Anca-Elena Eftenoiu, Roxana Popescu, Daliborca Cristina Vlad, Cristian Sebastian Vlad, Aurica Elisabeta Moatar, Daniela Puscasiu, Ionut Marcel Cobec Cancers.2024; 16(17): 3049. CrossRef
Male breast cancer: A multicenter study in Aragon over 27 years Olga Dobato Portoles, Daniel Aparicio Lopez, Reyes Ibañez Carreras, Elena Aguirre Ortega, Beatriz Eizaguirre Zarza, Carmen García Mur, Aurora Carrasquer Puyal, María Pilar Cebollero Benito, Laura Isabel Comín Novella, Marta Allue Cabañuz, Fernando Martine Cirugía Española (English Edition).2024; 102(10): 524. CrossRef
Male breast cancer: a 32-year retrospective analysis in radiation therapy referral center in northern Iran Mahboobeh Asgharian, Dariush Moslemi, Hossein-Ali Nikbakht, Mohammad-Ali Jahani, Ali Bijani, Hakimeh Mehdizadeh Annals of Medicine & Surgery.2024; 86(10): 5756. CrossRef
Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09) Jieun Lee, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Joohyuk Sohn, Gun Min Kim, Kyung-Hee Lee, Su Hwan Kang, Kyung Hae Jung, Jae-ho Jeong, Jae Ho Byun, Su-Jin Koh, Kyoung Eun Lee, Seungtaek Lim, Hee Jun Kim, Hye Sung Won, Hyung Soon Park, Guk Jin Lee, S Cancer Research and Treatment.2023; 55(1): 123. CrossRef
Clinicopathological features and correlation analysis of male breast cancer Lei Xi, Jinxing Zhou, Yan Wu, Rong Rong Medicine.2023; 102(30): e34408. CrossRef
Characteristics of metastasis and survival between male and female breast cancer with different molecular subtypes: A population‐based observational study Wentong Fang, Yue Huang, Xu Han, Jinghui Peng, Mingjie Zheng Cancer Medicine.2022; 11(3): 764. CrossRef
Comparison of short-term surgical outcomes between men and women with breast cancer: a retrospective study using nationwide inpatient data in Japan Takaaki Konishi, Michimasa Fujiogi, Nobuaki Michihata, Kojiro Morita, Hiroki Matsui, Kiyohide Fushimi, Masahiko Tanabe, Yasuyuki Seto, Hideo Yasunaga Breast Cancer Research and Treatment.2021; 186(3): 731. CrossRef
Ulcerated Nipple Nodule, Clinicopathologic Challenge: Answer Ahmad Adel, Mona R. E. Abdel-Halim, Yosra Abdel-Galeil The American Journal of Dermatopathology.2021; 43(6): 466. CrossRef
Genetic Landscape of Male Breast Cancer Fernando Augusto Batista Campos, Etienne Rouleau, Giovana Tardin Torrezan, Dirce Maria Carraro, José Claudio Casali da Rocha, Higor Kassouf Mantovani, Leonardo Roberto da Silva, Cynthia Aparecida Bueno de Toledo Osório, Solange Moraes Sanches, Sandrine M. Cancers.2021; 13(14): 3535. CrossRef
Treatment of male breast cancer: meta-analysis of real-world evidence A. P. Lin, T.-W. Huang, K.-W. Tam British Journal of Surgery.2021; 108(9): 1034. CrossRef
Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells Ana D. Pinzón-García, Ruben Sinisterra, Maria Cortes, Fredy Mesa, Sandra Ramírez-Clavijo PeerJ.2021; 9: e12124. CrossRef
Prognostic Factors in Male Breast Cancer: A Retrospective Nationwide Study in South Korea by the Study of SMARTSHIP Group Sungmin Park, Ho Hur, Ji Sung Lee, JaeSun Yoon, Sung Mo Hur, Il Yong Chung, Jong Won Lee, Hyun Jo Youn, Se Jeong Oh, Cheol Wan Lim, Jihyoun Lee Journal of Breast Cancer.2021; 24(6): 561. CrossRef
Meme Kanseri Cerrahisi Sonrası Lenfödem ve Uçak Seyahati Aysel GÜL, Dilek AYGİN İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi.2021; (15): 669. CrossRef
Italian Men Tested for BRCA1/2 Mutation: Psychological Distress during 6-Month Follow-Up F. Pellini, S. Mirandola, E. Granuzzo, S. Urbani, G. Piccinni Leopardi, G. P. Pollini Journal of Oncology.2020; 2020: 1. CrossRef
Comparing the Characteristics and Outcomes of Male and Female Breast Cancer Patients in Korea: Korea Central Cancer Registry Eun-Gyeong Lee, So-Youn Jung, Myong Cheol Lim, Jiwon Lim, Han-Sung Kang, Seeyoun Lee, Jai Hong Han, Heein Jo, Young-Joo Won, Eun Sook Lee Cancer Research and Treatment.2020; 52(3): 739. CrossRef
The effect of chemotherapy on survival in patients with nonmetastatic male breast cancer: A population‐based observational study Hong Pan, Kai Zhang, Ming Wang, Lijun Ling, Shui Wang, Wenbin Zhou Cancer.2020; 126(S16): 3830. CrossRef
Adjuvant Radiation Therapy for Male Breast Cancer—A Rare Indication? Tobias Forster, Clara Köhler, Rami El Shafie, Fabian Weykamp, Laila König, Nathalie Arians, Sebastian Adeberg, Laura Michel, Katharina Smetanay, Michael Golatta, Christof Sohn, Jörg Heil, Andreas Schneeweiss, Jürgen Debus, Juliane Hörner-Rieber Cancers.2020; 12(12): 3645. CrossRef
Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy Francesca Pellini, Eleonora Granuzzo, Silvia Urbani, Sara Mirandola, Marina Caldana, Davide Lombardi, Elena Fiorio, Marta Mandarà, Giovanni Paolo Pollini Breast Care.2020; 15(1): 14. CrossRef
Ultrasonographic and Mammographic Findings of Male Breast Disease Su Hong Kim, Young‐Seon Kim Journal of Ultrasound in Medicine.2019; 38(1): 243. CrossRef
Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study Paul Rogowski, Stephan Schönecker, Montserrat Pazos, Daniel Reitz, Michael Braun, Martin Pölcher, Claus Hanusch, Rachel Wuerstlein, Nadia Harbeck, Sven Mahner, Claus Belka, Stefanie Corradini Strahlentherapie und Onkologie.2019; 195(4): 289. CrossRef
Survival analysis for male ductal and lobular breast cancer patients with different stages Jizhao Wang, Yuchen Sun, Jingkun Qu, Huang Zuo, Xixi Zhao, Lin Liu, Jinteng Feng, Jiansheng Wang, Guangjian Zhang Future Oncology.2019; 15(2): 167. CrossRef
Clinical features of patients with male breast cancer in Shanxi province of China from 2007 to 2016 Weigang Wang, Xiaoqin Xu, Baoguo Tian, Yan Wang, Lili Du, Ting Sun, Yanchun Shi, Xianwen Zhao, Yali Jia, Yanfeng Xi, Jiexian Jing Journal of Investigative Medicine.2019; 67(3): 699. CrossRef
Metastasis pattern and prognosis of male breast cancer patients in US: a population-based study from SEER database Jun Xie, Yao-Yu Ying, Bin Xu, Yan Li, Xian Zhang, Chong Li Therapeutic Advances in Medical Oncology.2019;[Epub] CrossRef
Different Patterns of Conditional Survival of Breast Cancer Patients by Age and Histologic Types: Evidence from the Korean Nationwide Registry So-Youn Jung, Kyu-Won Jung, Johyun Ha, Young-Joo Won, Young Ae Kim, Youngmee Kwon, Sun-Young Kong, Eun Sook Lee Cancer Epidemiology, Biomarkers & Prevention.2019; 28(7): 1169. CrossRef
Diagnostic Value of Fine-Needle Aspiration in Male Breast Lesions Raza S. Hoda, Ronald N. Arpin III, Ravi V. Gottumukkala, Kevin S. Hughes, Amy Ly, Elena F. Brachtel Acta Cytologica.2019; 63(4): 319. CrossRef
The endocrinology of male breast cancer Ian S Fentiman Endocrine-Related Cancer.2018; 25(6): R365. CrossRef
Magee Equation Recurrence Score Is Associated With Distal Metastatic Risk in Male Breast Carcinomas Yanjun Hou, Harrison S Moosavi, Lai Wei, Anil V Parwani, Xiaoxian (Bill) Li, Zaibo Li American Journal of Clinical Pathology.2018; 150(6): 491. CrossRef
Axillary lymph node metastasis as the first manifestation of male occult breast cancer Xinyu Wang, Liwen Fan, Wenxing Yan, Qi Zhang, Shunchao Bao, Ying Wang, Xin Bao, Linlin Liu Medicine.2018; 97(50): e13706. CrossRef
A review of estrogen receptor/androgen receptor genomics in male breast cancer Tesa M Severson, Wilbert Zwart Endocrine-Related Cancer.2017; 24(3): R27. CrossRef
Imaging the Male Breast Shruthi Ram, Shadi Aminololama-Shakeri Current Radiology Reports.2017;[Epub] CrossRef
Mammary gland tumors in a male Cocker Spaniel Soon-Chan Kwon, Dae-Young Yoo, Minho Ko, Kwon-Young Lee, Ho-Hyun Kwak, In-Chul Park, In-Koo Hwang, Jung-Hoon Choi, Jin-Young Chung Acta Veterinaria Scandinavica.2017;[Epub] CrossRef
Male occult breast cancer with axillary lymph node metastasis as the first manifestation Ruixin Xu, Jianbin Li, Yingjie Zhang, Hongbiao Jing, Youzhe Zhu Medicine.2017; 96(51): e9312. CrossRef
Purpose
In Korea, most terminal cancer patients have still not been included in end-of-life (EOL) discussions. The purpose of this study was to evaluate the proportion of patients participating in EOL discussions after adopting advance directives.
Materials and Methods
Medical records of 106 hospice patients between July 2012 and February 2013 were reviewed retrospectively. The proportion of patient participation in EOL discussions, barriers, and favorable factors for completion of advance directives, as well as outcomes of advance directives were evaluated.
Results
Patient participation in EOL discussion had increased from 16/53 (30%) to 27/53 (51%) since adopting advance directives (p < 0.001). Median time between completion of an advance directive and death increased from 8 days (range, 0 to 22 days) to 14.5 days (range, 0 to 47 days). Patients’ poor condition after late referral was the main barrier to missing EOL discussions; however, family members’ concerns about patient’s distress was also a main reason for excluding the patient from EOL discussions. In univariate analysis, patient age, education status, and time from diagnosis to completion of an advance directive influenced advance directive completion favorably. Following multivariate analysis, higher education and periods of more than 2 years from diagnosis to completion of an advance directive remained favorable (odds ratio [OR], 9.586, p=0.024 and OR, 70.312; p=0.002). Preferences of all patients regarding cardiopulmonary resuscitation or hemodialysis were carried out by physicians. Orders for nutrition and palliative sedation showed discordance, with concordance rates of 74.2% and 51.6%, respectively.
Conclusion
Our results suggested that the use of advance directive promote patient participation in EOL discussion.
Citations
Citations to this article as recorded by
Participation and Influencing Factors in the Decision-Making of Life-Sustaining Treatment: A Focus on Deceased Patients with Hematologic Neoplasms Jae Eun Jang, Jeong Moon Ryu, Min Hee Heo, Do Eun Kwon, Ji Yeon Seo, Dong Yeon Kim The Korean Journal of Hospice and Palliative Care.2023; 26(2): 69. CrossRef
Discussing POLST-facilitated hospice care enrollment in patients with terminal cancer Ho Jung An, Hyun Jeong Jeon, Sang Hoon Chun, Hyun Ae Jung, Hee Kyung Ahn, Kyung Hee Lee, Min-ho Kim, Ju Hee Kim, Jaekyung Cheon, Su-Jin Koh Supportive Care in Cancer.2022; 30(9): 7431. CrossRef
A quantitative study of nurses perception to advance directive in selected private and public secondary healthcare facilities in Ibadan, Nigeria Oluwaseyi Emiola Ojedoyin, Ayodele Samuel Jegede BMC Medical Ethics.2022;[Epub] CrossRef
Influence of advance directives on reducing aggressive measures during end-of-life cancer care: A systematic review Lillian Ponchio e Silva Marchi, Martins Fideles dos Santos Neto, Júlia de Pauli Moraes, Carlos Eduardo Paiva, Bianca Sakamoto Ribeiro Paiva Palliative and Supportive Care.2021; 19(3): 348. CrossRef
A National Study of Life-Sustaining Treatments in South Korea: What Factors Affect Decision-Making? So-Youn Park, Bomyee Lee, Jeong Yeon Seon, In-Hwan Oh Cancer Research and Treatment.2021; 53(2): 593. CrossRef
The Situation of Life-Sustaining Treatment One Year after Enforcement of the Act on Decisions on Life-Sustaining Treatment for Patients at the End-of-Life in Korea: Data of National Agency for Management of Life-Sustaining Treatment Ha Yeon Lee, Hwa Jung Kim, Jung Hye Kwon, Sun Kyung Baek, Young-Woong Won, Yu Jung Kim, Su Jin Baik, Hyewon Ryu Cancer Research and Treatment.2021; 53(4): 897. CrossRef
Preparation and Practice of the Necessary Documents in Hospital for the “Act on Decision of Life-Sustaining Treatment for Patients at the End-of-Life” Sun Kyung Baek, Hwa Jung Kim, Jung Hye Kwon, Ha Yeon Lee, Young-Woong Won, Yu Jung Kim, Sujin Baik, Hyewon Ryu Cancer Research and Treatment.2021; 53(4): 926. CrossRef
Modifiable Factors Associated with the Completion of Advance Treatment Directives in Hematologic Malignancy: A Patient–Caregiver Dyadic Analysis JinShil Kim, Jinny Park, Mee Ok Lee, Eun Young Park, Seongkum Heo, Jae Lan Shim Journal of Palliative Medicine.2020; 23(5): 611. CrossRef
Nurses' perspectives on advance directives before the establishment of the new well-dying law in Korea: A mixed methods study Youn-Jung Son, JiYeon Choi, Jung-Won Ahn Applied Nursing Research.2020; 51: 151187. CrossRef
Hospital Nurses’ Perception of Death and Self-Reported Performance of End-of-Life Care: Mediating Role of Attitude towards End-of-Life Care Hyo-Jin Park, Yun-Mi Lee, Mi Hwa Won, Sung-Jun Lim, Youn-Jung Son Healthcare.2020; 8(2): 142. CrossRef
Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients Jung Sun Kim, Shin Hye Yoo, Wonho Choi, Yejin Kim, Jinui Hong, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo Cancer Research and Treatment.2020; 52(3): 917. CrossRef
Advance care planning in Asian culture Shao-Yi Cheng, Cheng-Pei Lin, Helen Yue-lai Chan, Diah Martina, Masanori Mori, Sun-Hyun Kim, Raymond Ng Japanese Journal of Clinical Oncology.2020; 50(9): 976. CrossRef
Family Members' Experience of Discussions on End-of-Life Care in Nursing Homes in Japan Hiroki Kato, Keiko Tamura Journal of Hospice & Palliative Nursing.2020; 22(5): 401. CrossRef
Efficacy of a Decision Aid Consisting of a Video and Booklet on Advance Care Planning for Advanced Cancer Patients: Randomized Controlled Trial Young Ho Yun, EunKyo Kang, Sohee Park, Su-Jin Koh, Ho-Suk Oh, Bhumsuk Keam, Young Rok Do, Won Jin Chang, Hyun Sik Jeong, Eun Mi Nam, Kyung Hae Jung, Hak Ro Kim, Jiyeon Choo, Jihye Lee, Jin-Ah Sim Journal of Pain and Symptom Management.2019; 58(6): 940. CrossRef
Effect of the duration of hospice and palliative care on the quality of dying and death in patients with terminal cancer: A nationwide multicentre study J.Y. Choi, K.A. Kong, Y.J. Chang, H.J. Jho, E.M. Ahn, S.K. Choi, S. Park, M.K. Lee European Journal of Cancer Care.2018; 27(2): e12771. CrossRef
End-of-Life Care and Discussions in Japanese Geriatric Health Service Facilities: A Nationwide Survey of Managing Directors’ Viewpoints Asako Kanoh, Yoshiyuki Kizawa, Satoru Tsuneto, Shoji Yokoya American Journal of Hospice and Palliative Medicine®.2018; 35(1): 83. CrossRef
Does special education in palliative medicine make a difference in end-of-life decision-making? Reetta P. Piili, Juho T. Lehto, Tiina Luukkaala, Heikki Hinkka, Pirkko-Liisa I. Kellokumpu-Lehtinen BMC Palliative Care.2018;[Epub] CrossRef
A Concept Analysis of End-of-life Discussions with Cancer Patients Midori Kadowaki Journal of Japan Academy of Nursing Science.2016; 36: 263. CrossRef
Ji Hyung Hong, Sung-Eun Lee, Soo Young Choi, Soo-Hyun Kim, Eun-Jung Jang, Ju-Hee Bang, Jin Eok Park, Hye-Rim Jeon, Yun Jeong Oh, Jeong-Eun Yi, Hae Ok Jung, Ho Joong Youn, Dong-Wook Kim
Cancer Res Treat. 2015;47(4):937-942. Published online November 17, 2014
We describe two cases of pulmonary arterial hypertension (PAH) that occurred under dasatinib treatment and were resolved after dasatinib discontinuation. Two patients with chronic phase chronic myeloid leukemia (CML) were switched to dasatinib therapy because of hematological progress while receiving imatinib. These patients had New York Heart Association (NYHA) functional class II dyspnea with elevated right ventricular systolic pressure (RVSP), which progressed under dasatinib treatment. After dasatinib treatment was discontinued, subjective symptoms were improved to NYHA functional class I and the follow-up transthoracic Doppler echocardiography showed improved RVSP. Treatment with an alternate tyrosine kinase inhibitor was initiated and had been continued without development of dyspnea or elevation of RVSP. This report suggests that dasatinib can cause the reversible PAH, therefore, routine cardiopulmonary evaluation before and during treatment with dasatinib may be needed in CML patients with clinical manifestations.
Citations
Citations to this article as recorded by
Prevalence and predictors of pulmonary hypertension in patients with myeloproliferative neoplasms: single-center study Mohamed Eid, Ali M Kasem, Yasser M Kamal, Mahmoud Hamdy, Mahmoud Gaber The Egyptian Journal of Haematology.2024; 49(1): 45. CrossRef
Relationship between Dasatinib-induced Pulmonary Hypertension and Drug Dose Kana Kubota, Yasushi Imai, Iekuni Oh, Shuichi Ueno, Yoshinobu Kanda, Kazuomi Kario Internal Medicine.2022; 61(15): 2263. CrossRef
Change of right ventricular systolic pressure can indicate dasatinib‐induced pulmonary arterial hypertension in chronic myeloid leukemia Sung‐Eun Lee, Jee Hyun Kong, Soo‐Hyun Kim, Eun‐Jung Jang, Nack‐Gyun Chung, Bin Cho, Suk Joong Oh, Hae‐Eok Jung, Ho‐Joong Youn, Woo‐Baek Chung, Dong‐Wook Kim Cancer Medicine.2021; 10(5): 1515. CrossRef
mTOR Signaling in Pulmonary Vascular Disease: Pathogenic Role and Therapeutic Target Aleksandra Babicheva, Ayako Makino, Jason X.-J. Yuan International Journal of Molecular Sciences.2021; 22(4): 2144. CrossRef
Dasatinib-Induced Pulmonary Arterial Hypertension: A Case Report Ru Liu, Yinjiang Tang, Ting Fu, Jianli Zhou, Lijiao Ma, Jinqing Yuan, Ou Xu Research Reports in Clinical Cardiology.2021; Volume 12: 33. CrossRef
Pulmonary hypertension in patients with chronic myeloid leukemia Ik-Chan Song, Sang-Hoon Yeon, Myeong-Won Lee, Hyewon Ryu, Hyo-Jin Lee, Hwan-Jung Yun, Byung Joo Sun, Jae-Hyeong Park, Jin-Ok Jeong, Deog-Yeon Jo Medicine.2021; 100(33): e26975. CrossRef
A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities Zahra Nekoukar, Minoo Moghimi, Ebrahim Salehifar BLOOD RESEARCH.2021; 56(4): 229. CrossRef
Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report Takumi Toya, Yuji Nagatomo, Kazuki Kagami, Takeshi Adachi, Julia Grapsa, Julia Grapsa, Hatem Soliman Aboumarie, Amir Aziz, Peysh A Patel European Heart Journal - Case Reports.2019;[Epub] CrossRef
Dasatinib‐induced pulmonary arterial hypertension Nurgül Özgür Yurttaş, Ahmet Emre Eşkazan British Journal of Clinical Pharmacology.2018; 84(5): 835. CrossRef
Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib Mariko Minami, Takeshi Arita, Hiromi Iwasaki, Tsuyoshi Muta, Takatoshi Aoki, Kenichi Aoki, Satoshi Yamasaki, Takamitsu Matsushima, Koji Kato, Katsuto Takenaka, Kazuki Tanimoto, Tomohiko Kamimura, Ryosuke Ogawa, Koichi Akashi, Toshihiro Miyamoto British Journal of Haematology.2017; 177(4): 578. CrossRef
Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib‐associated pulmonary arterial hypertension Arun Jose, Hind Rafei, Jalil Ahari Pulmonary Circulation.2017; 7(4): 803. CrossRef
Pulmonary arterial hypertension in a patient treated with dasatinib: a case report Andris Skride, Matiss Sablinskis, Kristaps Sablinskis, Krista Lesina, Aivars Lejnieks, Sandra Lejniece Journal of Medical Case Reports.2017;[Epub] CrossRef
Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease Diederik E. van der Feen, B. Bartelds, Rudolf A. de Boer, Rolf M.F. Berger European Heart Journal.2017; 38(26): 2034. CrossRef
PURPOSE It is important to balance the appropriateness of active cancer treatments and end-of-life care to improve the quality of life for terminally ill cancer patients. This study describes the treatment patterns and end-of-life care in terminal gastric cancer patients. MATERIALS AND METHODS We retrospectively analyzed the records of 137 patients with advanced gastric cancer receiving chemotherapy and dying between June 1, 2006 and May 31, 2011. We recorded interval between last chemotherapy dose and death; frequency of emergency room visits or admission to the intensive care unit in the last month before death; rate of hospice referral and agreement with written do-not-resuscitate orders; and change in laboratory values in the last three months before death. RESULTS During the last six months of life, 130 patients (94.9%) received palliative chemotherapy; 86 (62.7%) during the final two months; 41 (29.9%) during the final month.
During the final month, 53 patients (38.7%) visited an emergency room more than once; 21 (15.3%) were admitted to the intensive care unit. Hospice referral occurred in 54% (74 patients) of the patients; 93.4% (128 patients) gave written do-not-resuscitate orders. Platelets, aspartate aminotransferase and creatinine changed significantly two weeks before death; total bilirubin, one month before; and C-reactive protein, between four and two weeks before death. CONCLUSION Our results demonstrated that a significant proportion of gastric cancer patients received palliative chemotherapy to the end of life and the patients who stopped the chemotherapy at least one month before death had a lower rate of intensive care unit admission and longer overall survival than those who sustained aggressive chemotherapy until the last months of their lives.
Citations
Citations to this article as recorded by
Decreased aggressive care at the end of life among advanced cancer patients in the Republic of Korea: a nationwide study from 2012 to 2018 Sara Kwon, Kyuwoong Kim, Bohyun Park, So-Jung Park, Hyun Jung Jho, Jin Young Choi BMC Palliative Care.2024;[Epub] CrossRef
Automated machine learning (AutoML) can predict 90-day mortality after gastrectomy for cancer Gopika SenthilKumar, Sharadhi Madhusudhana, Madelyn Flitcroft, Salma Sheriff, Samih Thalji, Jennifer Merrill, Callisia N. Clarke, Ugwuji N. Maduekwe, Susan Tsai, Kathleen K. Christians, T. Clark Gamblin, Anai N. Kothari Scientific Reports.2023;[Epub] CrossRef
A prospective cohort study assessing aggressive interventions at the end-of-life among patients with solid metastatic cancer Chetna Malhotra, Filipinas Bundoc, Isha Chaudhry, Irene Teo, Semra Ozdemir, Eric Finkelstein, Rebecca A. Dent, Nesaretnam Barr Kumarakulasinghe, Yin Bun Cheung, Rahul Malhotra, Ravindran Kanesvaran, Alethea Chung Pheng Yee, Noreen Chan, Huei Yaw Wu, Soh M BMC Palliative Care.2022;[Epub] CrossRef
Quality of End-of-Life Care in Gastrointestinal Cancers: A 13-Year Population-Based Retrospective Analysis in Ontario, Canada Caitlin SR Lees, Hsien Seow, Kelvin KW Chan, Anastasia Gayowsky, Aynharan Sinnarajah Current Oncology.2022; 29(12): 9163. CrossRef
Use of Palliative Chemotherapy and ICU Admissions in Gastric and Esophageal Cancer Patients in the Last Phase of Life: A Nationwide Observational Study Joost Besseling, Jan Reitsma, Judith A. Van Erkelens, Maike H. J. Schepens, Michiel P. C. Siroen, Cathelijne M. P. Ziedses des Plantes, Mark I. van Berge Henegouwen, Laurens V. Beerepoot, Theo Van Voorthuizen, Lia Van Zuylen, Rob H. A. Verhoeven, Hanneke Cancers.2021; 13(1): 145. CrossRef
Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews M. Santero, J. Pérez-Bracchiglione, R. Acosta-Dighero, A. G. Meade, A. Antequera, A. Auladell-Rispau, M. J. Quintana, C. Requeijo, G. Rodríguez-Grijalva, K. Salas-Gama, R. Dorantes-Romandia, J. Salazar, I. Solà, G. Urrútia, X. Bonfill Cosp BMC Cancer.2021;[Epub] CrossRef
Health care utilization at end of life among patients with lung or pancreatic cancer. Comparison between two Swedish cohorts Helena Ullgren, Per Fransson, Anna Olofsson, Ralf Segersvärd, Lena Sharp, Amir Radfar PLOS ONE.2021; 16(7): e0254673. CrossRef
Health care utilization among patients with oesophageal and gastric cancer: the impact of initial treatment strategy and assignment of a contact nurse Karin Dalhammar, Marlene Malmström, Magnus Sandberg, Dan Falkenback, Jimmie Kristensson BMC Health Services Research.2021;[Epub] CrossRef
Conceptualizing and Counting Discretionary Utilization in the Final 100 Days of Life: A Scoping Review Paul R. Duberstein, Michael Chen, Michael Hoerger, Ronald M. Epstein, Laura M. Perry, Sule Yilmaz, Fahad Saeed, Supriya G. Mohile, Sally A. Norton Journal of Pain and Symptom Management.2020; 59(4): 894. CrossRef
The impact of initial treatment strategy and survival time on quality of end-of-life care among patients with oesophageal and gastric cancer: A population-based cohort study Karin Dalhammar, Marlene Malmström, Maria Schelin, Dan Falkenback, Jimmie Kristensson, Jason Chia-Hsun Hsieh PLOS ONE.2020; 15(6): e0235045. CrossRef
Outpatient Palliative Care and Aggressiveness of End-of-Life Care in Patients with Metastatic Colorectal Cancer Si Won Lee, Hyun Jung Jho, Ji Yeon Baek, Eun Kyung Shim, Hyun Mi Kim, Ji Yeon Ku, Eun Jung Nam, Yoon-Jung Chang, Hye Jin Choi, Sun Young Kim American Journal of Hospice and Palliative Medicine®.2018; 35(1): 166. CrossRef
Patterns and Yearly Time Trends in the Use of Radiation Therapy During the Last 30 Days of Life Among Patients With Metastatic Rectal Cancer in the United States From 2004 to 2012 Adan Z. Becerra, Christian P. Probst, Fergal J. Fleming, Zhaomin Xu, Christopher T. Aquina, Carla F. Justiniano, Courtney I. Boodry, Alex A. Swanger, Katia Noyes, Alan W. Katz, John R. Monson, Todd A. Jusko American Journal of Hospice and Palliative Medicine®.2018; 35(2): 336. CrossRef
Decreasing mortality and hospitalizations with rising costs related to gastric cancer in the USA: an epidemiological perspective Delong Liu, Dhruv Mehta, Supreet Kaur, Arun Kumar, Kaushal Parikh, Lavneet Chawla, Shanti Patel, Amirta Devi, Aparna Saha Journal of Hematology & Oncology.2018;[Epub] CrossRef
Frequency and Predictors of Acute Hospitalization Before Death in Patients With Glioblastoma Eli L. Diamond, Katherine S. Panageas, Alexis Dallara, Ariel Pollock, Allison J. Applebaum, Alan C. Carver, Elena Pentsova, Lisa M. DeAngelis, Holly G. Prigerson Journal of Pain and Symptom Management.2017; 53(2): 257. CrossRef
The effects of hospice-shared care for gastric cancer patients Kun-Siang Huang, Shih-Ho Wang, Seng-Kee Chuah, Kun-Ming Rau, Yu-Hung Lin, Meng-Che Hsieh, Li-Hsueh Shih, Yen-Hao Chen, Ramon Andrade de Mello PLOS ONE.2017; 12(2): e0171365. CrossRef
Clinical significance and predicting indicators of post‐cancer‐treatment survival in terminally ill patients with ovarian cancer Fumi Utsumi, Hiroaki Kajiyama, Kaoru Niimi, Ryuichiro Sekiya, Jun Sakata, Shiro Suzuki, Kiyosumi Shibata, Mika Mizuno, Fumitaka Kikkawa Journal of Obstetrics and Gynaecology Research.2017; 43(2): 365. CrossRef
Adopting Advance Directives Reinforces Patient Participation in End-of-Life Care Discussion Ji Hyung Hong, Jung Hye Kwon, Il Kyu Kim, Jin Hee Ko, Yi-Jin Kang, Hoon-Kyo Kim Cancer Research and Treatment.2016; 48(2): 753. CrossRef
Cases and Literature Review of Timing for Withdrawal of Palliative Chemotherapy Yun Jin Jeong, Do Yeun Kim The Korean Journal of Hospice and Palliative Care.2016; 19(1): 70. CrossRef
End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study I. Gallais Sérézal, Y. Beaussant, P. Rochigneux, C. Tournigand, R. Aubry, B. Lindelöf, L. Morin British Journal of Dermatology.2016; 175(3): 583. CrossRef
Trends in the Aggressiveness of End-of-Life Cancer Care in the State of Qatar Azza A. Hassan, Hassan Mohsen, Ayman A. Allam, Pascale Haddad Journal of Global Oncology.2016; 2(2): 68. CrossRef
Investigational tests and treatments performed in terminal stage cancer patients in two weeks before death: Turkish oncology group (TOG) study İbrahim Türker, Şeref Kömürcü, Ali Arıcan, Hatice Doruk, Özgür Özyılkan, Hasan Şenol Coşkun, Dilşen Çolak, Emel Üçgül Çavuşoğlu, Alper Ata, Ahmet Sezer, Havva Yeşil Çınkır, Filiz Çay Şenler, Fikret Arpacı Medical Oncology.2014;[Epub] CrossRef